Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30136% above fair value
$163.81−6.48 (-3.81%)
Close on Nov 20, 2026Market cap $10.47BP/E –Yield –
Repligen free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Repligen's free cash flow for the twelve months ending Sep 30, 2026 was $106.72M, down 3.0% year over year. For fiscal 2025 it was $93.90M, down 37.3% from the year before. Over ten years it grew 22.4% a year on average. The highest annual figure on record is $149.72M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.90M | -37.3% |
| FY2024 | Dec 31, 2024 | $149.72M | +92.7% |
| FY2023 | Dec 31, 2023 | $77.70M | -10.9% |
| FY2022 | Dec 31, 2022 | $87.25M | +68.0% |
| FY2021 | Dec 31, 2021 | $51.93M | +29.3% |
| FY2020 | Dec 31, 2020 | $40.17M | -17.5% |
| FY2019 | Dec 31, 2019 | $48.71M | +120.1% |
| FY2018 | Dec 31, 2018 | $22.14M | +84.5% |
| FY2017 | Dec 31, 2017 | $12.00M | +275.4% |
| FY2016 | Dec 31, 2016 | $3.20M | -74.3% |
| FY2015 | Dec 31, 2015 | $12.43M | -2.9% |
| FY2014 | Dec 31, 2014 | $12.80M | -39.9% |
| FY2013 | Dec 31, 2013 | $21.30M | +686.6% |
| FY2011 | Mar 31, 2011 | $2.71M | – |
| FY2010 | Mar 31, 2010 | -$3.05M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $38.15M | -12.1% |
| Q2 FY2026 | Jun 30, 2026 | $27.43M | +27.5% |
| Q1 FY2026 | Mar 31, 2026 | $23.59M | +106.1% |
| Q4 FY2025 | Dec 31, 2025 | $17.55M | -47.8% |
| Q3 FY2025 | Sep 30, 2025 | $43.40M | +2.5% |
| Q2 FY2025 | Jun 30, 2025 | $21.51M | -42.5% |
| Q1 FY2025 | Mar 31, 2025 | $11.44M | -68.5% |
| Q4 FY2024 | Dec 31, 2024 | $33.64M | +87.1% |
| Q3 FY2024 | Sep 30, 2024 | $42.34M | +37.3% |
| Q2 FY2024 | Jun 30, 2024 | $37.38M | +42.5% |
| Q1 FY2024 | Mar 31, 2024 | $36.36M | +1274.7% |
| Q4 FY2023 | Dec 31, 2023 | $17.98M | -56.6% |
| Q3 FY2023 | Sep 30, 2023 | $30.85M | +4.4% |
| Q2 FY2023 | Jun 30, 2023 | $26.23M | +28.9% |
| Q1 FY2023 | Mar 31, 2023 | $2.65M | – |
| Q4 FY2022 | Dec 31, 2022 | $41.44M | +136.8% |
| Q3 FY2022 | Sep 30, 2022 | $29.55M | +154.9% |
| Q2 FY2022 | Jun 30, 2022 | $20.35M | -3.8% |
| Q1 FY2022 | Mar 31, 2022 | -$4.09M | -343.8% |
| Q4 FY2021 | Dec 31, 2021 | $17.50M | +402.4% |
| Q3 FY2021 | Sep 30, 2021 | $11.59M | -34.6% |
| Q2 FY2021 | Jun 30, 2021 | $21.16M | +55.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.68M | -68.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.48M | -67.1% |
| Q3 FY2020 | Sep 30, 2020 | $17.71M | +8.0% |
| Q2 FY2020 | Jun 30, 2020 | $13.57M | -3.3% |
| Q1 FY2020 | Mar 31, 2020 | $5.40M | -29.8% |
| Q4 FY2019 | Dec 31, 2019 | $10.58M | +362.5% |
| Q3 FY2019 | Sep 30, 2019 | $16.40M | -1.9% |
| Q2 FY2019 | Jun 30, 2019 | $14.03M | +350.4% |
| Q1 FY2019 | Mar 31, 2019 | $7.70M | +96150.0% |
| Q4 FY2018 | Dec 31, 2018 | $2.29M | -83.0% |
| Q3 FY2018 | Sep 30, 2018 | $16.72M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.12M | +117.4% |
| Q1 FY2018 | Mar 31, 2018 | $8.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $13.45M | +1132.8% |
| Q3 FY2017 | Sep 30, 2017 | -$2.74M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.43M | – |
| Q1 FY2017 | Mar 31, 2017 | -$148.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.09M | – |
See a number that looks wrong?